Neuroimaging of phacomatoses;Neuro-imagerie des phacomatoses

Feuillets de Radiologie

Volumn 44, Issue 4, 2004, Pages

  Caron, S ^a   Soto Ares, G ^a   Vinchon, M ^a   Dhellemmes, P ^a   Pruvo, J P ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Genetic, tumor; Skin, tumor; White matter, tumor

Indexed keywords

ARTERY DYSPLASIA; ASTROCYTOMA; BONE DYSPLASIA; BRAIN AQUEDUCT STENOSIS; BRAIN CALCIFICATION; BRAIN VENTRICLE DILATATION; CAFE AU LAIT SPOT; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL FEATURE; EPILEPSY; FOLLOW UP; GENETIC ANALYSIS; HAMARTOMA; HEMANGIOBLASTOMA; HEMANGIOFIBROMA; HUMAN; MENINGIOMA; NEURILEMOMA; NEUROFIBROMATOSIS; NEUROFIBROSARCOMA; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE GLIOMA; PHAKOMATOSIS; PHEOCHROMOCYTOMA; PROGNOSIS; REVIEW; SCOLIOSIS; SKIN TUMOR; STURGE WEBER SYNDROME; TUBEROUS SCLEROSIS; VON HIPPEL LINDAU DISEASE;

EID: 19544385592     PISSN: 01819801     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0181-9801(04)94751-3     Document Type: Review

References (127)

1. Chateil JF, Brun M, Le Manh C, Diard F? Labrèze C. Phacomatoses chez l'enfant. Encycl Méd Chir, Radiodiagnostic - Neuroradiologie- Appareil locomoteur, 31-625-A-10, 2000, 23 p.
2. Chiron C, Méary E, Page P, Rodriguez D, Touzé E. Les phacomatoses. Neurologies 2002; 5: 105-23.
3. Osborn AG. Disorders of histogenesis: neurocutaneous syndromes. In: Diagnostic neuroradiology. Mosby-Year Book, Inc. 1994: 72-113.
4. Friedman JM. Neurofibromatosis 1: clinical manifestations and diagnostic criteria. J Child Neurol 2002; 17: 548-54.
5. De Goede-Bolder A, Cnossen MH, Dooijes D, van den Ouweland AM, Niermeijer MF. From gene to disease; neurofibromatosis type 1. Ned Tijdschr Geneeskd 2001; 145: 1736-8.
6. Korf BR. Diagnosis and management of neurofibromatosis type 1. Curr Neurol Neurosci Rep 2001; 1: 162-7.
7. Thomson SA, Fishbein L, Wallace MR. NF1 mutations and molecular testing. J Child Neurol 2002; 17: 555-61.
8. National Institutes of Health Consensus Development Conference Statement. Neurofibromatosis. Arch Neurol 1988; 45: 575-8.
9. Caldemeyer KS, Mirowski GW. Neurofibromatosis type 1. Part I. Clinical and central nervous system manifestations. J Am Acad Dermatol 2001; 44: 1025-6.
10. Pollack IF, Shultz B, Mulvihill JJ. The management of brainstem gliomas in patients with neurofibromatosis 1. Neurology 1996; 46: 1652-60.
11. Kuenzle C, Weissert M, Roulet E, Bode H, Schefer S, Huisman T et al. Follow-up of optic pathway gliomas in children with neurofibromatosis type 1. Neuropediatrics 1994; 25: 295-300.
12. e édition. Flammarion Médecine-Sciences, édit., Paris, 1998: 215-33.
13. Parazzini C, Triulzi F, Bianchini E, Agnetti V, Conti M, Zanolini C et al. Spontaneous involution of optic pathway lesions in neurofibromatosis type 1: serial contrast MR evaluation. AJNR 1995; 16: 1711-8.
14. Rossi LN, Triulzi F, Parazzini C, Maninetti MM. Spontaneous improvement of optic pathway lesions in children with neurofibromatosis type 1. Neuropediatrics 1999; 30: 205-9.
15. Mukonoweshuro W, Griffiths PD, Blaser S. Neurofibromatosis type 1: the role of neuroradiology. Neuropediatrics 1999; 30: 111-9.
16. Mikaeloff Y, Chaix Y, Grill J, Adamsbaum C, Bursztyn J, Rubie H et al. Optic pathway gliomas in neurofibromatosis type I. Longitudinal study of 30 cases in two multidisciplinary practices. Arch Pediatr 2002; 9: 797-804.
17. Herron J, Darrah R, Quaghebeur G. Intra-cranial manifestations of the neurocutaneous syndromes. Clin Radiol 2000; 55: 82-98.
18. North K, Joy P, Yuille D, Cocks N, Mobbs E, Hutchins P et al. Specific learning disability in children with neurofibromatosis type 1: significance of MRI abnormalities. Neurology 1994; 44: 878-83.
19. Arbuckle HA, Morelli JG. Pigmentary disorders: update on neurofibromatosis-1 and tuberous sclerosis. Curr Opin Pediatr 2000; 12: 354-8.
20. Lin J, Martel W. Cross-sectional imaging of peripheral nerve sheath tumors: characteristic signs on CT, MR imaging, and sonography. AJR 2001; 176: 75-82.
21. Karnes PS. Neurofibromatosis: a common neurocutaneous disorder. Mayo Clin Proc 1998; 73: 1071-6.
22. Janss A, Hiehle JF Jr, Yachnis AT. Neurofibromatosis type 1. Med Pediatr Oncol 1995; 25: 213-22.
23. Kornreich L, Blaser S, Schwarz M, Shuper A, Vishne TH, Cohen IJ et al. Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis. AJNR 2001; 22: 1963-9.
24. Chateil JF, Soussotte C, Pedespan JM, Brun M, Le Manh C, Diard F. MRI and clinical differences between optic pathway tumours in children with and without neurofibromatosis. Br J Radiol 2001; 74: 24-31.
25. Czyzyk E, Jozwiak S, Roszkowski M, Schwartz RA. Optic pathway gliomas in children with and without neurofibromatosis 1. J Child Neurol 2003; 18: 471-8.
26. Lovblad KO, Remonda L, Ozdoba C, Huber P, Schroth G. Dural ectasia of the optic nerve sheath in neurofibromatosis type 1: CT and MR features. J Comput Assist Tomogr 1994; 18: 728-30.
27. Broniscer A, Gajjar A, Bhargava R, Langsten JW, Heideman R, Jones D et al. Brain stem involvement in children with neurofibromatosis type 1: role of magnetic resonance imaging and spectroscopy in the distinction from diffuse pontine glioma. Neurosurgery 1997; 40: 331-8.
28. Molloy PT, Bilaniuk LT, Vaughan SN, Needle MN, Liu GT, Zackai EH et al. Brainstem tumors in patients with neurofibromatosis type 1: a distinct clinical entity. Neurology 1995; 45: 1897-902.
29. Bilaniuk LT, Molloy PT, Zimmerman RA, Phillips PC, Vaughan SN, Liu GT et al. Neurofibromatosis type 1: brain stem tumours. Neuroradiology 1997; 39: 642-53.
30. Decat V. Aspect IRM des lésions encéphaliques dans la neurofibromatose de type 1 chez l'enfant. Thèse. 1996.
31. Curless RG, Siatkowski M, Glaser JS, Shatz NJ. MRI diagnosis of NF-1 in children without cafe-au-lait skin lesions. Pediatr Neurol 1998; 18: 269-71.
32. Menor F, Marti-Bonmati L, Arana E, Poyatos C, Cortina H. Neurofibromatosis type 1 in children: MR imaging and follow-up studies of central nervous system findings. Eur J Radiol 1998; 26: 121-31.
33. Raininko R, Thelin L, Eeg-Olofsson O. Non-neoplastic brain abnormalities on MRI in children and adolescents with neurofibromatosis type 1. Neuropediatrics 2001; 32: 225-30.
34. Bonawitz C, Castillo M, Chin CT, Mukherji SK, Barkovich AJ. Usefulness of contrast material in MR of patients with neurofibromatosis type 1. AJNR 1998; 19: 541-6.
35. Yamanouchi H, Kato T, Matsuda H, Takashima S, Sakuragawa N, Arima M. MRI in neurofibromatosis type I: using fluid-attenuated inversion recovery pulse sequences. Pediatr Neurol 1995; 12: 286-90.
36. Terada H, Barkovich AJ, Edwards MS, Ciricillo SM. Evolution of high-intensity basal ganglia lesions on T1-weighted MR in neurofibromatosis type 1. AJNR 1996; 17: 755-60.
37. DiMario FJ Jr, Ramsby G. Magnetic resonance imaging lesion analysis in neurofibromatosis type 1. Arch Neurol 1998; 55: 500-5.
38. Itoh T, Magnaldi S, White RM, Denckla MB, Hofman K, Naidu S et al. Neurofibromatosis type 1: the evolution of deep gray and white matter MR abnormalities. AJNR 1994; 15: 1513-9.
39. Young H, Hyman S, North K. Neurofibromatosis 1: clinical review and exceptions to the rules. J Child Neurol 2002; 17: 613-21.
40. Sevick RJ, Barkovich AJ, Edwards MS, Koch T, Berg B, Lempert T. Evolution of white matter lesions in neurofibromatosis type 1: MR findings. AJR 1992; 159: 171-5.
41. DiPaolo DP, Zimmerman RA, Rorke LB, Zackai EH, Bilaniuk LT, Yachnis AT. Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain. Radiology 1995; 195: 721-4.
42. Adamsbaum C, Cohen PA. Quel est votre diagnostic? J Neuroradiol 1997; 24: 76-77.
43. Moore BD, Slopis JM, Schomer D, Jackson EF, Levy BM. Neuropsychological significance of areas of high signal intensity on brain MRIs of children with neurofibromatosis. Neurology 1996; 46: 1660-8.
44. Rosenbaum T, Engelbrecht V, Krolls W, van Dorsten FA, Hoehn-Berlage M, Lenard HG. MRI abnormalities in neurofibromatosis type 1 (NF1): a study of men and mice. Brain Dev 1999; 21: 268-73.
45. Jacquemin C, Bosley TM, Liu D, Svedberg H, Buhaliqa A. Reassessment of sphenoid dysplasia associated with neurofibromatosis type 1. AJNR 2002; 23: 644-8.
46. Inoue Y, Nemoto Y, Tashiro T, Nakayama K, Nakayama T, Daikokuya H. Neurofibromatosis type 1 and type 2: review of the central nervous system and related structures. Brain Dev 1997; 19: 1-12.
47. Steen RG, Taylor JS, Langsten JW, Glass JO, Brewer VR, Reddick WE et al. Prospective evaluation of the brain in asymptomatic children with neurofibromatosis type 1: relationship of macrocephaly to T1 relaxation changes and structural brain abnormalities. AJNR 2001; 22: 810-7.
48. Dubovsky EC, Booth TN, Vezina G, Samango-Sprouse CA, Palmer KM, Brasseux CO. MR imaging of the corpus callosum in pediatric patients with neurofibromatosis type 1. AJNR 2001; 22: 190-5.
49. Egelhoff JC, Bates DJ, Ross JS, Rothner AD, Cohen BH. Spinal MR findings in neurofibromatosis 1 and neurofibromatosis 2. AJNR 1992; 13: 1071-7.
50. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997; 278: 51-7.
51. Wolkenstein P, Freche B, Zeller J, Revuz J. Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients. Arch Dematol 1996; 132: 1333-6.
52. Pinson S, Creange A, Barbarot S, Stalder JF, Chaix Y, Rodriguez D et al. Neurofibromatose 1: recommandations de prise en charge. Arch Pediatr 2002; 9: 49-60.
53. Elster AD. Radiologic screening in the neurocutaneous syndromes: strategies and controversies. AJNR 1992; 13: 1078-82.
54. Griffiths PD, Blaser S, Mukonoweshuro W, Armstrong D, Milo-Mason G, Cheung S. Neurofibromatosis bright objects in children with neurofibromatosis type 1: a proliferative potential? Pediatrics 1999; 104: e49.
55. Caldemeyer KS, Mirowski GW. Neurofibromatosis type 2. J Am Acad Dermatol 2001; 45: 744-5.
56. Evans DG, Sainio M, Baser ME. Neurofibromatosis type 2. J Med Genet 2000; 37: 897-904.
57. Parry DM, MacCollin MM, Kaiser-Kupfer MI, Pulaski K, Nicholson HS, Bolesta M et al. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet 1996; 59: 529-39.
58. Zhao Y, Kumar RA, Baser ME, Evans DG, Wallace A, Kluwe L et al. Intrafamilial correlation of clinical manifestations in neurofibromatosis 2 (NF2). Genet Epidemiol 2002; 23: 245-59.
59. Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han FY, Chretien N et al. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 1996; 5: 331-42.
60. Merel P, Hoang-Xuan K, Sanson M, Bijlsma E, Rouleau G, Laurent-Puig P et al. Screening for germ-line mutations in the NF2 gene. Genes Chromosomes Cancer 1995; 12: 117-27.
61. Sainio M, Strachan T, Blomstedt G, Salonen O, Setala K, Palotie A et al. Presymptomatic DNA and MRI diagnosis of neurofibromatosis 2 with mild clinical course in an extended pedigree. Neurology 1995; 45: 1314-22.
62. Janse AJ, Tan WF, Majoie CB, Bijlsma EK. Neurofibromatosis type 2 diagnosed in the absence of vestibular schwannomas. A case report and guidelines for a screening protocol for children at risk. Eur J Pediatr 2001; 160: 439-43.
63. Goutebroze L, Giovannini M. Neurofibromatose de type 2. In: Oncogénétique. Lavoisier Tec et Doc. 1997: 233-43.
64. Mautner VF, Lindenau M, Baser ME, Hazim W, Tatagiba M, Haase W et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996; 38: 880-5.
65. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet 1992; 29: 847-52.
66. Smirniotopoulos JG, Murphy FM. The phakomatoses. AJNR 1992; 13: 725-46.
67. Akeson P, Hollas S. Radiological investigation of neurofibromatosis type 2. Neuroradiology 1994; 36: 107-10.
68. Patronas NJ, Courcoutsakis N, Bromley CM, Katzman GL, MacCollin M, Parry DM. Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. Radiology 2001; 218: 434-42.
69. Mautner VF, Tatagiba M, Lindenau M, Funsterer C, Pulst SM, Baser ME et al. Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety. AJR 1995; 165: 951-5.
70. Elster AD. Occult spinal tumors in neurofibromatosis: implications for screening. AJR 1995; 765: 956-7.
71. Evans DG, Newton V, Neary W, Baser ME, Wallace A, Macleod R et al. Use of MRI and audiological tests in presymptomatic diagnosis of type 2 neurofibromatosis (NF2). J Med Genet 2000; 37: 944-7.
72. Kleihues P, Cavenee WK, editors. Pathology and genetics of tumours of the nervous system. IARC Press. 2000: 215-41.
73. Sparagana SP, Roach ES. Tuberous sclerosis complex. Curr Opin Neurol 2000; 13: 115-9.
74. MacCollin M, Kwiatkowski D. Molecular genetic aspects of the phakomatoses: tuberous sclerosis complex and neurofibromatosis 1. Curr Opin Neurol 2001; 14: 163-9.
75. O'Callaghan FJ, Osborne JP. Advances in the understanding of tuberous sclerosis. Arch Dis Child 2000; 83: 140-2.
76. Mizuguchi M, Ikeda K, Takashima S. Simultaneous loss of hamartin and tuberin from the cerebrum, kidney and heart with tuberous sclerosis. Acta Neuropathol 2000; 99: 503-10.
77. Osborne JP, Jones AC, Burley MW, Jeganathan D, Young J, O'Callaghan FJ et al. Non-penetrance in tuberous sclerosis. Lancet 2000; 355: 1698.
78. Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001; 68: 64-80.
79. Crino PB, Henske EP. New developments in the neurobiology of the tuberous sclerosis complex. Neurology 1999; 53: 1384-90.
80. Griffiths PD, Martland TR. Tuberous Sclerosis Complex: the role of neuroradiology. Neuropediatrics 1997; 28: 244-52.
81. Christophe C, Sekhara T, Rypens F, Ziereisen F, Christiaens F, Dan B. MRI spectrum of cortical malformations in tuberous sclerosis complex. Brain Dev 2000; 22: 487-93.
82. Seidenwurm DJ, Barkovich AJ. Understanding tuberous sclerosis. Radiology 1992; 183: 23-4.
83. Braffman BH, Bilaniuk LT, Naidich TP, Altman NR, Post MJ, Quencer RM et al. MR imaging of tuberous sclerosis: pathogenesis of this phakomatosis, use of gadopentetate dimeglumine, and literature review. Radiology 1992; 183: 227-38.
84. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 1998; 13: 624-8.
85. Jozwiak S, Schwartz RA, Janniger CK, Michalowicz R, Chmielik J. Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance. Int J Dermatol 1998; 37: 911-7.
86. Caldemeyer KS, Mirowski GW. Tuberous sclerosis. Part I. Clinical and central nervous system findings. J Am Acad Dermatol 2001; 45: 448-9.
87. Takanashi J, Sugita K, Fujii K, Niimi H. MR evaluation of tuberous sclerosis: increased sensitivity with fluid-attenuated inversion recovery and relation to severity of seizures and mental retardation. AJNR 1995; 16: 1923-8.
88. Walz NC, Byars AW, Egelhoff JC, Franz DN. Supratentorial tuber location and autism in tuberous sclerosis complex. J Child Neurol 2002; 17; 830-2.
89. Shepherd CW, Houser OW, Gomez MR. MR findings in tuberous sclerosis complex and correlation with seizure development and mental impairment. AJNR 1995; 16: 149-55.
90. Roach ES, Williams DP, Laster DW. Magnetic resonance imaging in tuberous sclerosis. Arch Neurol 1987; 44: 301-3.
91. DiPaolo D, Zimmerman RA. Solitary cortical tubers. AJNR 1995; 16: 1360-4.
92. Barkovich AJ, Gressens P, Evrard P. Formation, maturation, and disorders of brain neocortex. AJNR 1992; 13: 423-46.
93. Kato T, Yamanouchi H, Sugai K, Takashima S. Improved detection of cortical and subcortical tubers in tuberous sclerosis by fluid-attenuated inversion recovery MRI. Neuroradiology 1997; 39: 378-80.
94. Maeda M, Tartaro A, Matsuda T, Ishii Y. Cortical and subcortical tubers in tuberous sclerosis and FLAIR sequence. J Comput Assist Tomogr 1995; 19: 660-1.
95. Baron Y, Barkovich AJ. MR imaging of tuberous sclerosis in neonates and young infants. AJNR 1999; 20: 907-16.
96. Van Tassel P, Cure JK, Holden KR. Cystlike white matter lesions in tuberous sclerosis. AJNR 1997; 18: 1367-73.
97. Nabbout R, Santos M, Rolland Y, Delalande O, Dulac O, Chiron C. Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis. J Neurol Neurosurg Psychiatry 1999; 66: 370-5.
98. Griffiths PD, Bolton P, Verity C. White matter abnormalities in tuberous sclerosis complex. Acta Radiol 1998; 39: 482-6.
99. Roach ES, DiMario FJ, Kandt RS, Northrup H. Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol 1999; 14: 401-7.
100. Hyman MH, Whittemore VH. National Institutes of Health consensus conference: tuberous sclerosis complex. Arch Neurol 2000; 57: 662-5.
101. Maher ER, Iselius L, Yates JR, Littler M, Benjamin C, Harris R et al. Von Hippel-Lindau disease: a genetic study. J Med Genet 1991; 28: 443-7.
102. Sgambati MT, Stolle C, Choyke PL, Walther MM, Zbar B, Linehan WM et al. Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents. Am J Hum Genet 2000; 66: 84-91.
103. Couch V, Lindor NM, Karnes PS, Michels VV. Von Hippel-Lindau disease. Mayo Clin Proc 2000; 75: 265-72.
104. Richard S. Maladie de von Hippel-Lindau. In: Oncogénétique. Lavoisier Tec et Doc. 1997: 233-43.
105. Zbar B, Kaeliri W, Maher E, Richard S. Third International Meeting on von Hippel-Lindau disease. Cancer Res 1999; 59: 2251-3.
106. Glasker S, Bender BU, Apel TW, Natt E, van Velthoven V, Scheremet R et al: The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system. J Neurol Neurosurg Psychiatry 1999; 67: 758-62.
107. Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B. von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology 1995; 194: 629-42.
108. Johnston LB, Chew SL, Trainer PJ, Reznek R, Grossman AB, Besser GM et al. Screening children at risk of developing inherited endocrine neoplasia syndromes. Clin Endocrinol 2000; 52: 127-36.
109. Niemela M, Lemeta S, Summanen P, Bohling T, Sainio M, Kere J et al. Long-term prognosis of haemangioblastoma of the CNS: impact of von Hippel-Lindau disease. Acta Neurochir 1999; 141: 1147-56.
110. Conway JE, Chou D, Clatterbuck RE, Brem H, Long DM, Rigamonti D. Hemangioblastomas of the central nervous system in von Hippel-Lindau syndrome and sporadic disease. Neurosurgery 2001; 48: 55-62.
111. Goto T, Nishi T, Kunitoku N, Yamamoto K, Kitamura I, Takeshima H et al. Suprasellar hemangioblastoma in a patient with von Hippel-Lindau disease confirmed by germline mutation study: case report and review of the literature. Surg Neurol 2001; 56: 22-6.
112. Cazals-Hatem D, Henin D, Bouccara D, Rey A, Cyna-Gorse F, Sterkers O. Endolymphatic sac tumor: a rare tumor of internal ear. Report of two cases. Ann Pathol 2000; 20: 349-52.
113. Joy HM, Barker CS, Millar JS, Davis A. Radiological considerations in the diagnosis of an endolymphatic sac tumour. Clin Radiol 2002; 57: 652-4.
114. Griffiths PD. Sturge-Weber syndrome revisited; the role of neuroradiology. Neuropediatrics 1996; 27: 284-94.
115. Enjorlas O. Malformations vasculaires complexes systématisé es. Rev Prat 1992; 42: 2048-52.
116. Decker T, Jones K, Barnes P. Sturge-Weber syndrome with posterior fossa involvement. AJNR 1994; 15: 389-92.
117. Enjorlas O, Riche MC, Merland JJ. Facial port-wine stains and Sturge-Weber syndrome. Pediatrics 1985; 76: 48-51.
118. Kramer U, Kahana E, Shorer Z, Ben-Zeev B. Outcome of infants with unilateral Sturge-Weber syndrome and early onset seizures. Dev Med Child Neurol 2000; 42: 756-9.
119. Benedikt RA, Brown DC, Walker R, Ghaed VN, Mitchell M, Geyer CA. Sturge-Weber syndrome: cranial MR imaging with Gd-DTPA. AJNR 1993; 14: 409-15.
120. Griffiths PD, Blaser S, Boodram MB, Armstrong D, Harwood-Nash D. Choroid plexus size in young children with Sturge-Weber syndrome. AJNR 1995; 17: 175-80.
121. Vogl TJ, Stemmler J, Bergman C. MR and MR angiography of Sturge-Weber syndrome. AJNR 1993; 14: 417-25.
122. Boukobza M, Enjorlas O, Cambra MR, Merland JJ. Syndrome de Sturge-Weber. Données actuelles de l'imagerie neuroradiologique. J Radiol 2000; 81: 765-71.
123. Adamsbaum C, Pinton F, Rolland Y, Chiron C, Dulac O, Kalifa G. Accelerated myelination in early Sturge-Weber syndrome: MRI-SPECT correlations. Pediatr Radiol 1996; 26: 759-62.
124. Portilla P, Husson B, Lasjaunias P, Landrieu P. Sturge-Weber disease with repercussion on the prenatal development of the cerebral hemisphere. AJNR 2002; 23: 490-2.
125. Griffiths PD, Boodram MB, Blaser S, Altomare F, Buncic JR, Levin AV et al. Abnormal ocular enhancement in Sturge-Weber syndrome: correlation of ocular MR and CT findings with clinical and intracranial imaging findings. AJNR 1995; 17: 749-54.
126. Antoun H, Adamsbaum C. Quel est votre diagnostic? J. Neuroradiol 2001; 28: 241-3.
127. Marti-Bonmati L, Menor L, Mulas F. The Sturge-Weber syndrome: correlation between the clinical status and radiological CT and MRI findings. Child's Nerv Syst 1993; 9: 107-9.